Thrombosis Research
Volume 125, Issue 5 , Pages e210-e213 , May 2010

Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D

  • Rolf Jorde

      Affiliations

    • Institute of Clinical Medicine, University of Tromsø, Norway
    • Medical Clinic, University Hospital of North Norway, Tromsø, Norway
    • Corresponding Author InformationCorresponding author. Medical Clinic, University Hospital of North Norway, 9038 Tromsø, Norway. Tel.: +47 776 26000; fax: +47 776 26863.
    • ,
  • Monica Sneve

      Affiliations

    • Department of Neurosurgery and Ophthalmology, Divison of Ophthalmology, University, Hospital of North Norway, 9038 Tromsø, Norway
    • ,
  • Peter Torjesen

      Affiliations

    • Hormone Laboratory, Aker University Hospital, Oslo, Norway
    • ,
  • Yngve Figenschau

      Affiliations

    • Department of Medical Biochemistry, University Hospital of North Norway, and Institute of Medical Biology, University of Tromsø, Tromsø, Norway
    • ,
  • John-Bjarne Hansen

      Affiliations

    • Center for Atherothrombotic Research in Tromsø (CART), Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway

Received 10 November 2009 ,Revised 5 December 2009 ,Accepted 17 December 2009.

References 

  1. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S–1696S
  2. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78:1193–1231
  3. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20:713–719
  4. Mattila C, Knekt P, Männistö S, Rissanen H, Laaksonen MA, Montonen J, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care. 2007;30:2569–2570
  5. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174–1180
  6. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–1637
  7. Lindqvist PG, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost. 2009;7:605–610
  8. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int J Epidemiol. 1981;10:337–341
  9. Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S. Anticoagulant effects of 1alpha, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood. 1998;92:160–167
  10. Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279:35798–35802
  11. Jorde R, Haug E, Figenschau Y, Hansen JB. Serum levels of vitamin D and haemostatic factors in healthy subjects: the Tromsø study. Acta Haematol. 2007;117:91–97
  12. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res. 2007;44:11–18
  13. Puri S, Bansal DD, Uskoković MR, MacGregor RR. Induction of tissue plasminogen activator secretion from rat heart microvascular cells by fM 1, 25(OH)(2)D(3). Am J Physiol Endocrinol Metab. 2000;278:E293–E301
  14. Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol. 2008;159:675–684
  15. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15
  16. Osmancevic A, Nilsen LT, Landin-Wilhelmsen K, Søyland E, Abusdal Torjesen P, Hagve TA, et al. Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis. J Eur Acad Dermatol Venereol. 2009;23:1133–1140
  17. Agledahl I, Brodin E, Svartberg J, Hansen JB. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels. Thromb Haemost. 2009;101:471–477
  18. Agledahl I, Brodin E, Svartberg J, Hansen JB. Impact of long-term testosterone treatment on plasma free TFPI levels and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Thromb Haemost 2009;102:945–50.
  19. Mannhalter C, Quehenberger P. Laboratory methods in the haemostatic laboratory. Thromb Haemost. 2006;96:545–546
  20. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138:769–774
  21. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327–1333
  22. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296:397–402
  23. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28
  24. Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays. 2003;25:1220–1228

PII: S0049-3848(09)00563-5

doi: 10.1016/j.thromres.2009.12.011

Thrombosis Research
Volume 125, Issue 5 , Pages e210-e213 , May 2010

Article Tools